Infliximab (Remicade®) is now approved in Europe for the treatment of ankylosing spondylitis (AS) patients who have severe axial symptoms, elevated serological markers of inflammatory activity and who have had an inadequate response to conventional therapy.
Arthritis News
Predictors and Frequency of Infection in RA Patients
[…]
Adalimumab (Humira) Receives FDA Approval
[…]
Cytokine Traps: Novel Anti-Cytokine Blockers
[…]
Adalimumab (Humira) is Safe and Effective When Administered Concomitantly with Standard Anti-Rheumatic Therapy for the Treatment of Rheumatoid Arthritis (RA)
[…]
HMGB-1 Plays a Role in the Pathogenesis of Arthritis from Johns Hopkins Arthritis
[…]
